Johnson & Johnson (NYSE:JNJ): Bernstein expects the recent product launches by Johnson & Johnson’s pharmaceutical unit to cause the unit’s growth to accelerate. The firm believes that the Synthes acquisition improves the company’s competitive positioning and growth profile, and it reiterates an Outperform rating on the stock.
Harley-Davidson, Inc. (NYSE:HOG): UBS believes Harley-Davidson May U.S. retail sales are up approximately mid-single digits bringing U.S. retails sales up 14%-15% year-to-date. The firm believes Q2 sales are up 5%-6% and FY12 sales could be up 9% year-over-year. Shares are Neutral rated with a $50 price target.
Nuance Communications, Inc. (NASDAQ:NUAN): UBS recommends looking past the market noise and reiterates it positive view on Nuance. The analyst said the Healthcare business has returned to double digit growth and mobile penetration is accelerating. The firm views valuation as attractive and reiterates its Buy rating and $30 price target.
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): After meeting with management, Jefferies believes any acquisition offers for Amylin would have to be at least in the low-to-mid $30s to be considered. Jefferies thinks Amylin will feel pressure to make strategic decisions on its independence by September and keeps a Buy rating on the stock with a $32 price target.
Guess? Inc. (NYSE:GES): Jefferies thinks the market may rally after the Greek elections take place this weekend and said it would be buying Guess shares aggressively ahead of the event. The firm thinks Guess is well positioned as investors begin to focus on companies with Europe exposure that have been under pressure. Jefferies still believes Guess shares can double and keeps a Buy rating on the name with a $50 price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.